IVDAWHIGH SIGNALFINANCIAL10-K

IVDAW showed meaningful improvement in cash position and profitability while eliminating going concern language, indicating strengthened financial stability.

The removal of going concern language from the risk factors represents a material positive development, suggesting management believes the company has addressed its near-term liquidity challenges. The substantial improvement in operating cash flow combined with nearly doubled cash reserves indicates the company has stabilized its financial position after previous distress.

Comparing 2026-03-31 vs 2025-04-15View on EDGAR →
FINANCIAL ANALYSIS

IVDAW demonstrated notable financial improvement with operating cash flow losses narrowing meaningfully and cash reserves roughly doubling to $5.2M. The balance sheet strengthened considerably with stockholders' equity growing substantially and current liabilities declining by 45%, while accounts receivable dropped sharply, possibly indicating improved collections or timing differences. The combination of reduced R&D expenses and significantly lower interest expense contributed to overall cost structure improvement, painting a picture of a company that has successfully navigated through financial distress.

FINANCIAL STATEMENT CHANGES
Capital Expenditure
Cash Flow
-99.7%
$878K$3K

Capex reduced 99.7% — investment cycle winding down or capital discipline; may improve near-term free cash flow.

Cash & Equivalents
Balance Sheet
+96.1%
$2.6M$5.2M

Cash position surged 96.1% — strong cash generation or capital raise providing significant financial cushion.

Stockholders Equity
Balance Sheet
+90.8%
$2.5M$4.8M

Equity base grew 90.8% — retained earnings accumulation or equity issuance strengthening the balance sheet.

Interest Expense
P&L
-86.4%
$53K$7K

Interest expense declined — debt repayment or refinancing at lower rates improving earnings quality.

Accounts Receivable
Balance Sheet
-79.9%
$1.3M$257K

Receivables declined — improved collection efficiency or conservative revenue recognition.

Inventory
Balance Sheet
+59.3%
$148K$236K

Inventory surged 59.3% — growing significantly faster than typical sales pace; potential demand softening or supply chain overcorrection.

Operating Cash Flow
Cash Flow
+54.1%
-$4.4M-$2.0M

Operating cash flow surged 54.1% — exceptional cash generation, highest quality earnings signal.

R&D Expense
P&L
-53%
$363K$171K

R&D spending cut 53% — could signal cost discipline or concerning reduction in innovation investment.

Current Liabilities
Balance Sheet
-44.8%
$2.3M$1.3M

Current liabilities reduced — improved short-term financial position and working capital health.

Total Assets
Balance Sheet
+24.1%
$5.2M$6.4M

Asset base grew 24.1% — expansion through organic growth, acquisitions, or capital deployment.

LANGUAGE CHANGES
NEW — 2026-03-31
PRIOR — 2025-04-15
ADDED
As of March 15, 2026, there were outstanding 11,139,740 shares of the registrant s common stock, par value $ 0.00001 per share.
The Company received shareholder approval for the issuance of shares of Common Stock underlying warrants issued in our September 2024 offering at the August 29, 2025 reconvened 2024 Annual Meeting.
Our LevelNOW product utilized Cerebro on a per device license basis during 2025.
For the years ended December 31, 2025 and 2024, we incurred net losses of approximately $3.2 million and $4.0 million, respectively, and had accumulated losses of approximately $56 million through December 31, 2025.
Revenue from four customers out of approximately 70 total customers represented approximately 63% of total revenue for the year ended December 31, 2025.
+7 more — sign up free →
REMOVED
As of March 31, 2025, there were outstanding 2,808,071 shares of the registrant s common stock, par value $ 0.00001 per share.
Since the Company did not receive shareholder approval for the issuance of shares of Common Stock underlying warrants issued in our September 2024 offering, the Annual Meeting was adjourned to June 2, 2025 to allow for additional time to obtain votes for this proposal.
Our LevelNOW product will be utilizing Cerebro on a per device license basis during 2025.
Risks Related to Our Company and Business Our financial statements contain a going concern opinion.
The accompanying consolidated financial statements have been prepared assuming that we will continue as a going concern, which contemplates the realization of assets and the liquidation of liabilities in the normal course of business.
+7 more — sign up free →
MORE FINANCIAL SIGNALS
CRMHIGHSalesforce significantly increased debt by 71% to $14.4B while simultaneously ac...
2026-03-02
UNHHIGHUNH's operating income plummeted 41% despite 12% revenue growth, indicating seve...
2026-03-02
PFEHIGHPfizer achieved a dramatic 87.3% reduction in total debt from $31.4B to $4.0B, r...
2026-02-26
GILDHIGHGILD dramatically increased R&D spending by 81.5% to $9.1B while introducing new...
2026-02-24
ANALYZE ANY FILING FREE

See what changed in your portfolio's filings

500+ US-listed companies analyzed. Language delta, financial analysis, instant signal scoring.

Try Tracenotes free →